サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1379173

血液悪性腫瘍市場：世界の産業動向、シェア、規模、成長、機会、予測、2023-2028年

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 148 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.94円
血液悪性腫瘍市場：世界の産業動向、シェア、規模、成長、機会、予測、2023-2028年
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界の血液悪性腫瘍市場規模は2022年に553億米ドルに達しました。今後、IMARC Groupは、2022～2028年の成長率（CAGR）は9.1％を示し、2028年には932億米ドルに達すると予測しています。

リンパ腫、白血病、多発性骨髄腫などの血液悪性腫瘍は、血液を産生する細胞のがんです。これらの細胞は、傷を凝固させるための血小板、酸素を運搬するための赤血球（RBC）、免疫防御のための白血球（WBC）で構成され、骨髄の造血幹細胞や前駆細胞に由来します。血液悪性腫瘍は、顕微鏡検査、細胞遺伝学、免疫表現型分類、フローサイトメトリー、蛍光in situハイブリダイゼーション（FISH）、ポリメラーゼ連鎖反応（PCR）、遺伝子発現プロファイリングなどの検査を用いて診断することができます。現在では、診断検査に基づく治療のために、抗腫瘍抗生物質、ヒストン脱アセチル化酵素阻害剤、ヤヌスキナーゼ（JAK）阻害剤など、いくつかの薬剤が世界中で入手可能です。

血液悪性腫瘍市場の動向：

急性骨髄性白血病（AML）の罹患率は高齢者層で比較的高いです。このことは、平均寿命の伸びと相まって、世界中で血液悪性腫瘍治療薬の需要を喚起する重要な要因の一つとなっています。これに加えて、免疫組織化学（IHC）の進歩により、組織サンプルを細胞分子や抗原に対する様々な抗体にさらすことで、血液悪性腫瘍を正確に診断できるようになっています。このことが市場の成長を強めています。さらに、診断方法の改善とともに、早期診断に対する意識が高まっていることも、市場の成長に寄与しています。これとは別に、穿孔、閉塞、狭窄などのリンパ腫合併症の組織診断と治療には外科療法が利用できます。このことは、CAR T細胞療法やbrexucabtagene autoleuceなどの高価格薬剤の複数の新規療法や複数の適応拡大の発売と相まって、市場の成長を促進しています。さらに、進行性血液悪性腫瘍患者向けに先進的な薬剤を導入するための臨床研究が進行中であることも、今後数年間の市場を牽引すると予想されます。

本レポートで扱う主な質問

  • 世界の血液悪性腫瘍市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の血液悪性腫瘍市場に与えた影響は？
  • 主要な地域市場は？
  • タイプ別の市場内訳は？
  • 療法に基づく市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の血液悪性腫瘍市場の構造と主要プレーヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 血液悪性腫瘍の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 白血病
    • 市場動向
    • 市場予測
  • リンパ腫
    • 市場動向
    • 市場予測
  • 多発性骨髄腫
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：療法別

  • 化学療法
    • 市場動向
    • 市場予測
  • 放射線療法
    • 市場動向
    • 市場予測
  • 免疫療法
    • 市場動向
    • 市場予測
  • 幹細胞移植
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 診断センター
    • 市場動向
    • 市場予測
  • 研究センター
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2022
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2022
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players
目次
Product Code: SR112023A4133

Abstract

The global hematologic malignancies market size reached US$ 55.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 9.1% during 2022-2028.

Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.

Hematologic Malignancies Market Trends:

The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapy and end user.

Breakup by Type:

Leukemia

Lymphoma

Multiple Myeloma

Others

Breakup by Therapy:

Chemotherapy

Radiotherapy

Immunotherapy

Stem Cell Transplantation

Others

Breakup by End User:

Hospitals

Diagnostics Centers

Research Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis